Tumor shrinkage evaluation during and after preoperative doxorubicin and cyclophosphamide followed by docetaxel in patients with breast cancer

Fabio Puglisi, Mauro Mansutti, Giuseppe Aprile, Alessandro Marco Minisini, Carla Di Loreto, Massimo Bazzocchi, Viviana Londero, Carla Cedolini, Giuliana Gentile, Stefano Pizzolitto, Andrea Piga, Alberto Sobrero

Research output: Contribution to journalArticle

Abstract

Aim: To evaluate the relative activity of the sequential administration of doxorubicin and cyclophosphamide (AC) followed by docetaxel alone, as primary systemic therapy in patients with breast cancer, using an in vivo chemosensitivity predictive assay. Patients and Methods: Patients with stage II-III breast cancer received two cycles of AC (60/600 mg/m2 every 3 weeks) followed by two cycles of docetaxel (100 mg/m2 every 3 weeks). All patients underwent comprehensive breast imaging prior to chemotherapy, after two AC and after docetaxel. Results: Forty-two patients were accrued and evaluated by intention-to-treat analysis. After two cycles of AC, the median tumor shrinkage was 18.3%, whereas treatment with docetaxel provided an additional median tumor shrinkage of 34.2%. Pathological complete remission was observed in 5 patients (11.9%), whereas 26 patients (61.9%) experienced a partial response. Conclusion: The relative contribution of docetaxel to tumor mass reduction seemed to be greater than that of AC. However, the slow rate of tumor shrinkage observed may indicate that the activity of the first 2 cycles of AC is carried over into the part of treatment with docetaxel.

Original languageEnglish
Pages (from-to)2487-2493
Number of pages7
JournalAnticancer Research
Volume24
Issue number4
Publication statusPublished - Jul 2004

Fingerprint

docetaxel
Doxorubicin
Cyclophosphamide
Breast Neoplasms
Neoplasms
Intention to Treat Analysis
Breast
Therapeutics

Keywords

  • Breast cancer
  • Cyclophosphamide
  • Docetaxel
  • Doxorubicin

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Tumor shrinkage evaluation during and after preoperative doxorubicin and cyclophosphamide followed by docetaxel in patients with breast cancer. / Puglisi, Fabio; Mansutti, Mauro; Aprile, Giuseppe; Minisini, Alessandro Marco; Di Loreto, Carla; Bazzocchi, Massimo; Londero, Viviana; Cedolini, Carla; Gentile, Giuliana; Pizzolitto, Stefano; Piga, Andrea; Sobrero, Alberto.

In: Anticancer Research, Vol. 24, No. 4, 07.2004, p. 2487-2493.

Research output: Contribution to journalArticle

Puglisi, F, Mansutti, M, Aprile, G, Minisini, AM, Di Loreto, C, Bazzocchi, M, Londero, V, Cedolini, C, Gentile, G, Pizzolitto, S, Piga, A & Sobrero, A 2004, 'Tumor shrinkage evaluation during and after preoperative doxorubicin and cyclophosphamide followed by docetaxel in patients with breast cancer', Anticancer Research, vol. 24, no. 4, pp. 2487-2493.
Puglisi, Fabio ; Mansutti, Mauro ; Aprile, Giuseppe ; Minisini, Alessandro Marco ; Di Loreto, Carla ; Bazzocchi, Massimo ; Londero, Viviana ; Cedolini, Carla ; Gentile, Giuliana ; Pizzolitto, Stefano ; Piga, Andrea ; Sobrero, Alberto. / Tumor shrinkage evaluation during and after preoperative doxorubicin and cyclophosphamide followed by docetaxel in patients with breast cancer. In: Anticancer Research. 2004 ; Vol. 24, No. 4. pp. 2487-2493.
@article{b6ef9e1ed5dd42ceaf380fc86ebb786c,
title = "Tumor shrinkage evaluation during and after preoperative doxorubicin and cyclophosphamide followed by docetaxel in patients with breast cancer",
abstract = "Aim: To evaluate the relative activity of the sequential administration of doxorubicin and cyclophosphamide (AC) followed by docetaxel alone, as primary systemic therapy in patients with breast cancer, using an in vivo chemosensitivity predictive assay. Patients and Methods: Patients with stage II-III breast cancer received two cycles of AC (60/600 mg/m2 every 3 weeks) followed by two cycles of docetaxel (100 mg/m2 every 3 weeks). All patients underwent comprehensive breast imaging prior to chemotherapy, after two AC and after docetaxel. Results: Forty-two patients were accrued and evaluated by intention-to-treat analysis. After two cycles of AC, the median tumor shrinkage was 18.3{\%}, whereas treatment with docetaxel provided an additional median tumor shrinkage of 34.2{\%}. Pathological complete remission was observed in 5 patients (11.9{\%}), whereas 26 patients (61.9{\%}) experienced a partial response. Conclusion: The relative contribution of docetaxel to tumor mass reduction seemed to be greater than that of AC. However, the slow rate of tumor shrinkage observed may indicate that the activity of the first 2 cycles of AC is carried over into the part of treatment with docetaxel.",
keywords = "Breast cancer, Cyclophosphamide, Docetaxel, Doxorubicin",
author = "Fabio Puglisi and Mauro Mansutti and Giuseppe Aprile and Minisini, {Alessandro Marco} and {Di Loreto}, Carla and Massimo Bazzocchi and Viviana Londero and Carla Cedolini and Giuliana Gentile and Stefano Pizzolitto and Andrea Piga and Alberto Sobrero",
year = "2004",
month = "7",
language = "English",
volume = "24",
pages = "2487--2493",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "4",

}

TY - JOUR

T1 - Tumor shrinkage evaluation during and after preoperative doxorubicin and cyclophosphamide followed by docetaxel in patients with breast cancer

AU - Puglisi, Fabio

AU - Mansutti, Mauro

AU - Aprile, Giuseppe

AU - Minisini, Alessandro Marco

AU - Di Loreto, Carla

AU - Bazzocchi, Massimo

AU - Londero, Viviana

AU - Cedolini, Carla

AU - Gentile, Giuliana

AU - Pizzolitto, Stefano

AU - Piga, Andrea

AU - Sobrero, Alberto

PY - 2004/7

Y1 - 2004/7

N2 - Aim: To evaluate the relative activity of the sequential administration of doxorubicin and cyclophosphamide (AC) followed by docetaxel alone, as primary systemic therapy in patients with breast cancer, using an in vivo chemosensitivity predictive assay. Patients and Methods: Patients with stage II-III breast cancer received two cycles of AC (60/600 mg/m2 every 3 weeks) followed by two cycles of docetaxel (100 mg/m2 every 3 weeks). All patients underwent comprehensive breast imaging prior to chemotherapy, after two AC and after docetaxel. Results: Forty-two patients were accrued and evaluated by intention-to-treat analysis. After two cycles of AC, the median tumor shrinkage was 18.3%, whereas treatment with docetaxel provided an additional median tumor shrinkage of 34.2%. Pathological complete remission was observed in 5 patients (11.9%), whereas 26 patients (61.9%) experienced a partial response. Conclusion: The relative contribution of docetaxel to tumor mass reduction seemed to be greater than that of AC. However, the slow rate of tumor shrinkage observed may indicate that the activity of the first 2 cycles of AC is carried over into the part of treatment with docetaxel.

AB - Aim: To evaluate the relative activity of the sequential administration of doxorubicin and cyclophosphamide (AC) followed by docetaxel alone, as primary systemic therapy in patients with breast cancer, using an in vivo chemosensitivity predictive assay. Patients and Methods: Patients with stage II-III breast cancer received two cycles of AC (60/600 mg/m2 every 3 weeks) followed by two cycles of docetaxel (100 mg/m2 every 3 weeks). All patients underwent comprehensive breast imaging prior to chemotherapy, after two AC and after docetaxel. Results: Forty-two patients were accrued and evaluated by intention-to-treat analysis. After two cycles of AC, the median tumor shrinkage was 18.3%, whereas treatment with docetaxel provided an additional median tumor shrinkage of 34.2%. Pathological complete remission was observed in 5 patients (11.9%), whereas 26 patients (61.9%) experienced a partial response. Conclusion: The relative contribution of docetaxel to tumor mass reduction seemed to be greater than that of AC. However, the slow rate of tumor shrinkage observed may indicate that the activity of the first 2 cycles of AC is carried over into the part of treatment with docetaxel.

KW - Breast cancer

KW - Cyclophosphamide

KW - Docetaxel

KW - Doxorubicin

UR - http://www.scopus.com/inward/record.url?scp=4444270896&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4444270896&partnerID=8YFLogxK

M3 - Article

C2 - 15330203

AN - SCOPUS:4444270896

VL - 24

SP - 2487

EP - 2493

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 4

ER -